For patients with certain rare forms of lung cancer, therapeutic advances have long been limited. But an international study presented at the 2026 American Society of Clinical Oncology (ASCO) Congress and published simultaneously in the New England Journal of Medicine could reshuffle the cards. Sunvozertinib, a targeted therapy administered orally, provided better disease control than standard chemotherapy in patients with a particularly difficult-to-treat genetic mutation. A promising advance, which however raises questions among certain specialists as to its future place in the therapeutic arsenal.
A rare mutation that has long left patients without a real solution
Not all lung cancers are the same. Behind the same diagnosis today hide dozens of different biological profiles, each with its own mechanisms and sensitivity to treatments. Over the past fifteen years, the identification of certain genetic anomalies has enabled the development of targeted therapies which have profoundly transformed the prognosis of many patients. But some mutations still resist.
This is the case for insertions of exon 20 of the EGFR gene, a rare anomaly observed in a small proportion of patients with non-small cell lung cancer. These tumors are distinguished by their aggressiveness and their low sensitivity to the first generations of targeted treatments developed against EGFR.
For a long time, doctors have had to deal with imperfect treatment options.
Dr. John Heymach, an oncologist at the University of Texas MD Anderson Cancer Center and lead author of the study, sums up this reality:
“For years, lung cancer patients with EGFR exon 20 insertion mutations experienced a poor prognosis because available treatments were either poorly effective or highly toxic.”.
It is in this context that sunvozertinib was developed, a molecule designed specifically to target this particular genetic anomaly.
The ambition is simple: to neutralize with greater precision the molecular engine that fuels the growth of these tumors while limiting the toxicity associated with conventional treatments.
Encouraging results compared to standard chemotherapy
To evaluate the effectiveness of this new approach, researchers launched the international phase III WU-KONG28 trial.
A total of 324 patients with advanced lung cancer harboring an EGFR exon 20 insertion were recruited. Participants were divided into two groups: one received sunvozertinib as a daily tablet, the other received standard chemotherapy combining carboplatin and pemetrexed.
The results presented at ASCO caught the attention of the oncology community:
- Progression-free survival — that is, the length of time the disease does not get worse — reached more than 10 months in patients treated with sunvozertinib, compared to 7.5 months in those receiving chemotherapy;
- Another striking data: the targeted treatment made it possible to obtain a reduction in the size of the tumors in almost 59% of patients, compared to approximately 31% in the group treated with chemotherapy;
- The researchers also report a longer median duration of response: 11.2 months with sunvozertinib compared to 7.1 months with chemotherapy.
For Dr John Heymach, these results demonstrate more effective control of the disease:
“These results show that sunvozertinib provides better disease control and shrinks tumors more frequently than chemotherapy.”.
Beyond the figures, this advance could represent a significant change in the daily lives of patients. Unlike protocols administered by infusion in hospital, sunvozertinib is taken orally, at home. An apparent simplicity that can have a considerable impact on quality of life when treatments are long-term.
Between hope and caution: the questions that remain to be resolved
However, the story is not yet written. As is often the case in oncology, a promising scientific advance must be placed in a broader therapeutic context.
Asked about these results, Dr. Ivan Pourmir, oncologist and researcher, believes that sunvozertinib actually constitutes “a small sign of hope” for patients facing this disease. He recalls that the treatments currently used in first line often combine chemotherapy and targeted therapy, with sometimes significant toxicity. As such, “Having an oral alternative is obviously good news” underlines the expert.
The specialist nevertheless advises not to draw conclusions too quickly. According to him, the study does not compare sunvozertinib to the treatment considered today as the reference in several countries, in particular the chemotherapy-amivantamab combination. A direct comparison will be necessary to precisely determine the place of the new drug.
Other elements also call for caution. The adverse effects observed are not negligible, including diarrhea and nail damage reported in certain patients.
Finally, the majority of participants included in the trial were Asian. However, certain analyzes suggest that the observed benefit could be more marked in this population. Additional data will be needed to confirm the effectiveness of the treatment in more diverse populations.
However, researchers highlight several reassuring signals. Only 7.4% of patients discontinued treatment due to adverse reactions, and no drug-related deaths were observed during the study. For Dr Pourmir, the conclusion is nuanced but optimistic:
“As things currently stand, this study will probably not immediately change anything in French practices. But it undoubtedly opens an interesting avenue for the future.”.
In an area where every month gained against illness counts, this avenue actually deserves to be followed closely. Sunvozertinib does not yet constitute a therapeutic revolution. But it illustrates a fundamental trend which is gradually transforming modern oncology: that of ever more personalized medicine, capable of adapting treatments to the genetic particularities of each tumor.
For patients carrying this rare mutation, long deprived of truly satisfactory options, this development already represents real hope.